ANGION BIOMEDICA CORPORATION

Company Information

Company Name
ANGION BIOMEDICA CORPORATION
Address
51 Charles Lindbergh Blvd
Uniondale, NY, 11553-3658
Phone
n/a
URL
n/a
DUNS
53129065
Number of Employees
31
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$11,303,973.00
48
SBIR Phase II
$47,805,572.00
25
Chart code to be here

Award List

  1. A Pilot Clinical Study in Acute STEMI

    Amount: $2,914,839.00

    DESCRIPTION (provided by applicant): Percutaneous coronary intervention (PCI) has become the mainstay for treatment of ST-segment elevation myocardial infarction (STEMI). Whereas early recanalization ...

    SBIR Phase II 2010 Department of Health and Human Services
  2. Anti-Fibrotic Therapy for Scleroderma/SSc

    Amount: $287,606.00

    DESCRIPTION (provided by applicant): Scleroderma (also known as systemic sclerosis-SSc) is an autoimmune disorder characterized primarily by progressive dermal and vascular fibrosis. Other organs are ...

    SBIR Phase I 2010 Department of Health and Human Services
  3. Therapeutic Potential of PARP inhibitor for Acute Pancreatitis

    Amount: $219,145.00

    DESCRIPTION (provided by applicant): Acute Pancreatitis (AP) is a potentially lethal inflammatory disease of the pancreas. Its pathogenesis remains obscure and is involved in a process of acute inflam ...

    SBIR Phase I 2010 Department of Health and Human Services
  4. Phase I Clinical Study Using an Antifibrotic Drug

    Amount: $311,292.00

    DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of people worldwide, is the liver scarring response to chronic injury from excessive alcohol use, virus infect ...

    SBIR Phase I 2010 Department of Health and Human Services
  5. Treatment for alcoholic liver disease

    Amount: $238,482.00

    DESCRIPTION (provided by applicant): Liver fibrosis is a form of scar formation that is found in almost all patients with chronic injury to the liver. Over time it frequently progresses to cirrhosis, ...

    SBIR Phase I 2010 Department of Health and Human Services
  6. A Novel Therapeutic for Chronic Kidney Disease

    Amount: $391,296.00

    DESCRIPTION: Chronic kidney disease (CKD) remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates r ...

    SBIR Phase I 2010 Department of Health and Human Services
  7. Antifibrotic Therapy for Chronic Kidney Disease

    Amount: $271,934.00

    DESCRIPTION (provided by applicant): Chronic kidney disease remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition t ...

    SBIR Phase I 2010 Department of Health and Human Services
  8. PDGFR and KDR Inhibitors for Liver Fibrosis

    Amount: $269,786.00

    DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of patients worldwide, is the liver scarring response to chronic injury from viral hepatitis B or C, excessive ...

    SBIR Phase I 2010 Department of Health and Human Services
  9. N/A

    Amount: $115,754.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services
  10. N/A

    Amount: $117,834.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government